Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$6,373 Mln
Revenue (TTM)
$46 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.2 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
10.4
Industry P/E
--
EV/EBITDA
244.6
Div. Yield
0 %
Debt to Equity
0
Book Value
$9.6
EPS
$-2
Face value
--
Shares outstanding
63,808,716
CFO
$-498.42 Mln
EBITDA
$-614.20 Mln
Net Profit
$-607.32 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Protagonist Therapeutics (PTGX)
| 18.7 | 12.6 | 18.7 | 114.4 | 65.2 | 32.0 | -- |
|
BSE Sensex*
| -15.4 | -11.9 | -15.9 | -5.8 | 6.7 | 7.4 | 11.0 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Protagonist Therapeutics (PTGX)
| 126.3 | 67.6 | 110.2 | -68.1 | 69.6 | 186.0 | 4.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Protagonist Therapeutics (PTGX)
|
103.7 | 6,372.6 | 46.0 | -130.2 | -313.8 | -20.2 | -- | 10.4 |
| 62.9 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 228.2 | 13,405.2 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 14.6 | |
| 66.6 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 44.0 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 91.2 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 7.1 | 6,847.2 | 113.3 | -351.4 | -211.0 | 71.1 | -- | 0.0 | |
| 529.8 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 489.5 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 319.3 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and... older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California. Address: 7707 Gateway Boulevard, Newark, CA, United States, 94560 Read more
CEO, President, Secretary & Director
Dr. Dinesh V. Patel Ph.D.
CEO, President, Secretary & Director
Dr. Dinesh V. Patel Ph.D.
Headquarters
Newark, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Protagonist Therapeutics Inc (PTGX) is $103.67 (NASDAQ) as of 01-Apr-2026 16:00 EDT. Protagonist Therapeutics Inc (PTGX) has given a return of 65.19% in the last 3 years.
Since, TTM earnings of Protagonist Therapeutics Inc (PTGX) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-42.95
|
9.09
|
|
2024
|
9.12
|
3.72
|
|
2023
|
-16.55
|
3.88
|
|
2022
|
-4.33
|
2.48
|
|
2021
|
-12.53
|
5.24
|
The 52-week high and low of Protagonist Therapeutics Inc (PTGX) are Rs 107.84 and Rs 39.60 as of 02-Apr-2026.
Protagonist Therapeutics Inc (PTGX) has a market capitalisation of $ 6,373 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Protagonist Therapeutics Inc (PTGX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-1.73
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.